NCT05805319 Dietary Intervention for NSCLC Patients Treated With ICI
| NCT ID | NCT05805319 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Condition | Non Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-04-27 |
| Primary Completion | 2025-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-04-27 with a primary completion date of 2025-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.
Eligibility Criteria
Inclusion Criteria: * Signed, informed consent * Age 18 years or older * Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI * Ability to eat solid foods Exclusion Criteria: * Severe dietary allergies (e.g. shellfish, nuts, seafood) * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Contact & Investigator
Bertrand Routy, MD,PhD
PRINCIPAL INVESTIGATOR
CHUM
Frequently Asked Questions
Who can join the NCT05805319 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05805319 currently recruiting?
Yes, NCT05805319 is actively recruiting participants. Contact the research team at wiam.belkaid.chum@ssss.gouv.qc.ca for enrollment information.
Where is the NCT05805319 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05805319 clinical trial?
NCT05805319 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The principal investigator is Bertrand Routy, MD,PhD at CHUM. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.